Repare Therapeutics Stock Alpha and Beta Analysis
| RPTX Stock | USD 2.81 0.16 5.39% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Repare Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Repare Therapeutics over a specified time horizon. Remember, high Repare Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Repare Therapeutics' market risk premium analysis include:
Beta 1 | Alpha (0.12) | Risk 4.44 | Sharpe Ratio (0.02) | Expected Return (0.09) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Repare |
Repare Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Repare Therapeutics market risk premium is the additional return an investor will receive from holding Repare Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Repare Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Repare Therapeutics' performance over market.| α | -0.12 | β | 1.00 |
Repare Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Repare Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Repare Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Repare Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Repare Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Repare Therapeutics shares will generate the highest return on investment. By understating and applying Repare Therapeutics stock market price indicators, traders can identify Repare Therapeutics position entry and exit signals to maximize returns.
Repare Therapeutics Return and Market Media
The median price of Repare Therapeutics for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 is 3.37 with a coefficient of variation of 8.69. The daily time series for the period is distributed with a sample standard deviation of 0.29, arithmetic mean of 3.29, and mean deviation of 0.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Repare Therapeutics stock hits 52-week low at 2.76 By Investing.com - Investing.com UK | 09/04/2024 |
2 | Repare Therapeutics to Present Data from Phase 12 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-o... | 09/13/2024 |
3 | Repare Therapeutics Inc. institutional owners may be pleased with recent gains after 68 percent loss over the past year | 09/16/2024 |
4 | Repare Therapeutics Inc. is definitely on the radar of institutional investors who own 36 percent of the company | 09/27/2024 |
5 | Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol ATPase Inhibitor | 10/14/2024 |
6 | Disposition of 825 shares by Steve Forte of Repare Therapeutics at 4.62 subject to Rule 16b-3 | 10/18/2024 |
7 | Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial | 10/23/2024 |
8 | Acquisition by Rhoads Ann D of 27200 shares of Repare Therapeutics at 3.8 subject to Rule 16b-3 | 11/01/2024 |
9 | Repare Therapeutics GAAP EPS of -0.81 | 11/07/2024 |
10 | Repare Therapeutics collaborates with U.S. National Cancer Institute | 11/12/2024 |
11 | Analysts Revenue Estimates For Repare Therapeutics Inc. Are Surging Higher | 11/13/2024 |
About Repare Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Repare or other stocks. Alpha measures the amount that position in Repare Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 10.01 | 4.5 | 6.24 | 5.92 | Net Debt To EBITDA | 3.05 | 8.65 | 0.94 | 0.9 |
Repare Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Repare Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Repare Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Repare Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Repare Therapeutics. Please utilize our Beneish M Score to check the likelihood of Repare Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Repare Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.